Abnormal Sodium and Chlorine Level Is Associated With Prognosis of Lung Cancer Patients

Objective: The imbalance of sodium and chloride ions occurs frequently in patients with lung cancer. However, the correlation between ion concentration change and patients prognosis have not been studied thoroughly. Our research will fill the gap, especially for high ion concentration. Methods: We retrospectively studied inpatients diagnosed with primary NSCLC and treated between May 2015 and July 2017. The basic clinical information and blood test data before and after treatment were collected. According to the clinical reference range of normal ion concentration, the patients were divided into three groups: low, normal and high level. Kaplan-Meier curve was used to analyze the difference of overall survival (OS) prognosis among each group. The correlation between ion concentration and other clinical parameters was further analyzed. Finally, a prognostic nomogram model was established by LASSO-COX method. Results: In the 1237 patients cohort, the median follow-up period was 861 days (range 3-2128 days). Firstly, 6 serum ions were included in the study, and only sodium (Na) and chloride (cl) ions were significantly associated with OS. Low level patients were found nearly just in III-IV stage patients, in contrast, high level patients distribute evenly in all stages. Then, correlation analysis showed that increased Na and cl concentrations were associated with decreased neutrophil number and elevated lymphocyte proportion. Finally, prognostic model analysis showed that cl is a crucial parameter. Conclusion: Serum Na and cl ion concentrations are closely related to the OS of lung cancer patients, and should be considered as clinical prognostic factors.

[1]  Lei Wu,et al.  Pretreatment Low Serum Sodium as a Prognostic Factor for Patients with Esophageal Cancer Treated with Radiotherapy or Chemoradiotherapy , 2022, Journal of oncology.

[2]  A. Awasthi,et al.  High-salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity , 2021, Science advances.

[3]  F. Tan,et al.  Association between pre‐diagnostic serum albumin and cancer risk: Results from a prospective population‐based study , 2021, Cancer medicine.

[4]  J. Rathmell,et al.  Ex Vivo High Salt Activated Tumor-Primed CD4+T Lymphocytes Exert a Potent Anti-Cancer Response , 2021, Cancers.

[5]  N. Aggerholm-Pedersen,et al.  Hyponatremia in lung cancer: Incidence and prognostic value in a Danish population-based cohort study. , 2021, Lung cancer.

[6]  Junfeng Zhang,et al.  High-salt diet inhibits tumour growth in mice via regulating myeloid-derived suppressor cell differentiation , 2020, Nature Communications.

[7]  I. Asangani,et al.  Tumor-Derived Retinoic Acid Regulates Intratumoral Monocyte Differentiation to Promote Immune Suppression , 2020, Cell.

[8]  J. Shim,et al.  Hypernatremia at admission predicts poor survival in patients with terminal cancer: a retrospective cohort study , 2020, BMC Palliative Care.

[9]  A. Peri,et al.  Effects of low extracellular sodium on proliferation and invasive activity of cancer cells in vitro , 2019, Endocrine.

[10]  T. Wurdinger,et al.  Tumor-educated platelets. , 2019, Blood.

[11]  N. Beerenwinkel,et al.  Neutrophils escort circulating tumour cells to enable cell cycle progression , 2019, Nature.

[12]  Min K. Tsai,et al.  An Lkb1-Sik axis suppresses lung tumor growth and controls differentiation. , 2019, Cancer discovery.

[13]  S. Kannan,et al.  Prognostic significance of pretreatment sodium levels in patients of nonsmall cell lung cancer treated with pemetrexed-platinum doublet chemotherapy , 2018, Journal of Cancer Research and Therapeutics.

[14]  W. Jochum,et al.  Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. , 2017, Lung cancer.

[15]  Frank C. Detterbeck,et al.  The Eighth Edition Lung Cancer Stage Classification , 2017, Chest.

[16]  T. Dubose,et al.  Hyponatremia in the cancer patient. , 1993, Oncology.